AIDS
Conditions
Interventions
Liver and kidney essence deficiency treatment group:HAART treatment + Chinese medicine "Diwu Yanggan Capsule" treatment
control group:The usual care group received HAART only
Lung spleen deficiency treatment group:HAART treatment + Chinese medicine "Fuzheng Kangai Granules" treatment
Sponsors
Hubei Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? HIV antibody positive, confirmed by Western Blot confirmation test; ? Voluntary acceptance of HAART; ? CD4+ cell count <350 cells/µL; ? The subjects are between 18-65 years old, male or female; ? TCM syndrome differentiation is in line with lung-spleen deficiency syndrome or liver-kidney essence deficiency syndrome; ? Voluntarily participate in this study, sign the informed consent form, and follow up on time.
Exclusion criteria
Exclusion criteria: ? Those with uncontrolled serious opportunistic infections (Pneumocystis pneumonia, meningitis, esophageal Candida infection, lymphoma, Toxoplasma encephalopathy, tuberculosis, etc.) before enrollment; ? Patients who are participating in clinical trials of other drugs within 1 month before enrollment; ? Those who received immunomodulatory therapy within 1 month before enrollment; ? White blood cell (WBC) count <2.0×109/L, or neutrophil (N) count <1.0×109/L, or hemoglobin (Hb) amount <90g/L, or platelet (PLT) count <75×109 /L, or liver or renal insufficiency (aspartate aminotransferase (AST), aspartate aminotransferase (ALT), total bilirubin (TBIL) = 2 times the upper limit of the reference value or urea nitrogen (BUN) ), serum creatinine (Scr) detection value = 1.2 times the upper limit of the reference value); ? Patients with pancreatitis and active gastric ulcer; ? Patients with clinically significant active diseases of the respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, and urogenital system; ? Those who suffer from autoimmune diseases; ? Tumor patients who need chemotherapy; ? Pregnant or breastfeeding women and women of childbearing age who do not use safe contraception; ? allergic constitution; ? Patients with intellectual or language barriers who cannot fully understand the test content or give good cooperation; ? Other circumstances that the investigator considers inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T cell subsets;TCM syndrome score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Comorbidity rate;Opportunistic infection incidence and mortality;HIV/AIDS PRO Scale;HIV viral load;inflammatory markers; | — |
Countries
China
Contacts
Public ContactLiu Jianzhong
Hubei Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed